IL299103A - Formulations of activin A antibody and methods of its use - Google Patents

Formulations of activin A antibody and methods of its use

Info

Publication number
IL299103A
IL299103A IL299103A IL29910322A IL299103A IL 299103 A IL299103 A IL 299103A IL 299103 A IL299103 A IL 299103A IL 29910322 A IL29910322 A IL 29910322A IL 299103 A IL299103 A IL 299103A
Authority
IL
Israel
Prior art keywords
activin
methods
antibody formulations
antibody
formulations
Prior art date
Application number
IL299103A
Other languages
English (en)
Hebrew (he)
Inventor
Douglas Kamen
Kenneth Graham
Original Assignee
Regeneron Pharma
Douglas Kamen
Kenneth Graham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Douglas Kamen, Kenneth Graham filed Critical Regeneron Pharma
Publication of IL299103A publication Critical patent/IL299103A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL299103A 2020-06-18 2021-06-18 Formulations of activin A antibody and methods of its use IL299103A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040589P 2020-06-18 2020-06-18
PCT/US2021/038016 WO2021257947A1 (en) 2020-06-18 2021-06-18 Activin a antibody formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
IL299103A true IL299103A (en) 2023-02-01

Family

ID=77168377

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299103A IL299103A (en) 2020-06-18 2021-06-18 Formulations of activin A antibody and methods of its use

Country Status (13)

Country Link
US (1) US12472253B2 (https=)
EP (1) EP4168038A1 (https=)
JP (1) JP7850084B2 (https=)
KR (1) KR20230026407A (https=)
CN (1) CN116322768A (https=)
AU (1) AU2021293577A1 (https=)
BR (1) BR112022025700A2 (https=)
CA (1) CA3183316A1 (https=)
CL (1) CL2022003586A1 (https=)
CO (1) CO2023000264A2 (https=)
IL (1) IL299103A (https=)
MX (1) MX2022016403A (https=)
WO (1) WO2021257947A1 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
MA46046A (fr) 2016-08-29 2019-07-03 Regeneron Pharma Anticorps anti-gremlin-1 (grem1) et procédés d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
CN111655288A (zh) * 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
MX2020008991A (es) * 2018-03-01 2020-12-10 Regeneron Pharma Metodos para alterar la composicion corporal.

Also Published As

Publication number Publication date
US12472253B2 (en) 2025-11-18
CN116322768A (zh) 2023-06-23
JP7850084B2 (ja) 2026-04-22
CL2022003586A1 (es) 2023-07-21
BR112022025700A2 (pt) 2023-02-28
JP2023532203A (ja) 2023-07-27
CA3183316A1 (en) 2021-12-23
EP4168038A1 (en) 2023-04-26
CO2023000264A2 (es) 2023-01-26
KR20230026407A (ko) 2023-02-24
MX2022016403A (es) 2023-04-11
WO2021257947A1 (en) 2021-12-23
AU2021293577A1 (en) 2023-02-09
US20210393779A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
GB202019709D0 (en) Anti-Coronavirus antibodies and methods of use
IL285285A (en) Pairs of il-2 and their uses
LT4267105T (lt) Antikūnų kompozicijos ir jų panaudojimo būdai
IL289813A (en) Antibody against tau and its use
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
ES3064823T3 (en) Anti-ly6g6d antibodies and methods of use
SG11202108403UA (en) Anti-clec2d antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL299245A (en) LAIR-1 binding agents and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
SI4200018T1 (sl) Protitelesa proti-PAR-2 in postopki njihove uporabe
SG11202103907PA (en) Formulations of anti-rsv antibodies and methods of use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL298668B1 (en) Anti-CD200R1 antibodies and methods of using them
SG11202111672RA (en) Cancer associated antibody compositions and methods of use
IL288886A (en) Antibodies and methods of use
IL310028A (en) Antibody and its use
IL308260A (en) Antibodies against Tigit and methods of using them
IL299103A (en) Formulations of activin A antibody and methods of its use
IL300104A (en) Antibody specific for mucin-1 and methods of using it
AU2021352981A9 (en) Anti-cd94 antibodies and methods of use thereof
HK40092927A (en) Activin a antibody formulations and methods of use thereof
HK40108234A (en) Anti-gal3 antibody formulations and methods of use thereof
EP3595776A4 (en) FLUTICASONE SUSTAINED-RELEASE FORMULATIONS AND THEIR PROCEDURES FOR USE
IL309310A (en) Antibody formulations against TGF-beta and their use